Compare Dollar Tree, Inc. (DLTR) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dollar Tree, Inc. vs Enveric Biosciences Inc — how do they compare? Dollar Tree, Inc. trades at $127.65 (market cap $24.86B), while Enveric Biosciences Inc trades at $1.45 (market cap $6.20M). The key difference: Dollar Tree, Inc. is far larger — about 4009.7× Enveric Biosciences Inc's market cap, and Dollar Tree, Inc. is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| DLTR | ENVB | |
|---|---|---|
Market Cap | $24.86B | $6.20M |
Sector | Health | Health |
52-Week High | $141.21 | $17.40 |
52-Week Low | $85.04 | $1.27 |
Enterprise Value | $31.45B | $1.30M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dollar Tree (DLTR) trades at $130.9, up 0.94% on the day, with a bullish technical outlook and strong profitability metrics including a 34.71% ROE. Recent quarters have consistently beaten EPS estimates, and the company announced a $2.5 billion share repurchase authorization in July 2026. Revenue for 2025 was $17.58 billion, though net income was negative due to a significant tax charge, with a rebound to profitability projected for 2026.
The stock presents a mixed outlook: analyst consensus is a 'Buy' with a $129.08 price target near the current price, supported by solid cash flow and margin improvements. Key risks include competitive pressures, tariff impacts on margins, and execution of the turnaround strategy amid consumer spending shifts.
ENVB trades at $1.55, down 0.64% with a bullish technical signal despite negative profitability. The company shows promising clinical progress with its lead candidate EB-003, supported by recent FDA guidance and positive preclinical data. While quarterly earnings consistently beat expectations, the company remains unprofitable with negative ROE and ROA. Analyst sentiment is positive with 75% buy ratings.
Investment outlook hinges on successful drug development milestones, with regulatory progress and intellectual property expansion providing catalysts. Key risks include clinical trial outcomes, cash burn from operations, and dependence on financing activities. The stock presents speculative growth potential for risk-tolerant investors focused on biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Dollar Tree, Inc.
Dollar Tree operates discount stores in the U.S. and Canada, including 8,647 shops under its namesake banner and 8,016 Family Dollar units (as of the end of fiscal 2021). The eponymous chain features branded and private-label goods, generally at a $1.25 price. Around 45% of Dollar Tree stores' fiscal 2021 sales came from consumables (including food, health and beauty, and household paper and cleaning products), nearly 50% from variety items (including toys and housewares), and just over 5% from seasonal goods. Family Dollar features branded and private-label goods at prices generally ranging from $1 to $10, with over 76% of fiscal 2021 sales from consumables, 9% from seasonal/electronic items (including prepaid phones and toys), 8% from home products, and 6% from apparel and accessories.
Read more on DLTR →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
